Keypoints:
• CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer.
• Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes.
• NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies.
• IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates.
• DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care.
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain had the pleasure of discussing the latest and most impactful findings from the ASCO 2025 meeting, particularly focusing on lung cancer. We were joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center, who provided valuable insights into five key studies that could potentially change clinical practice.
We kicked off our discussion with the CheckMate 816 study, which revealed significant overall survival benefits for patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant chemotherapy combined with nivolumab. The five-year survival rates showed a notable improvement, prompting us to consider the implications for our treatment approaches.
Next, we explored a fascinating study on the timing of immunotherapy, which demonstrated that patients receiving treatment earlier in the day had significantly better progression-free survival (PFS) and overall survival (OS). This finding raises intriguing questions about the relationship between circadian rhythms and immune response, and we discussed the need for further research in this area.
We then shifted our focus to the EGFR-mutated lung cancer space, where the NeoADAURA trial examined the use of osimertinib in the neoadjuvant setting. While the adjuvant use of osimertinib is already established, the implications of this new data are still being evaluated, and we expressed caution in changing our current practices without more long-term data.
In the realm of small cell lung cancer (SCLC), we discussed two pivotal studies: IMforte and DeLLphi 304. Both studies demonstrated overall survival benefits, marking a significant advancement in a disease that has historically had poor outcomes. Dr. Liu shared his experiences with the IMforte trial, emphasizing the importance of maintenance therapy and the need to manage toxicities effectively.
Finally, we touched on the promising results from the DeLLphi 304 study, which introduced tarlatamab as a new treatment option in the second-line setting for SCLC. While the efficacy is exciting, we acknowledged the logistical challenges associated with its administration.
Overall, this episode highlighted the rapid advancements in lung cancer treatment and the importance of staying informed about emerging data. We encourage our listeners to consider these findings in their practice and to continue advocating for their patients. Thank you for joining us, and be sure to check out our other conference highlights!
Listen Podcast on Your Favourite Platform
